There’s a tendency in this industry to focus on the visible breakthroughs.
New modalities. Novel delivery systems. First-in-class therapies. Those are the things that get attention, and understandably so. But behind every one of those advancements is a thought process with a layer of work that rarely gets attention… and obviously, without it, none of those programs can advance in the next stage of drug development.
It’s first and foremost the analytical methods that determine what’s actually happening in a drug formulation. The stability studies determine whether a product can survive different environmental conditions. The iterative development work is required for fixing problems before they become major setbacks.
It’s not the part of drug development that gets highlighted. But it’s often the part that decides whether something succeeds or stalls.
As therapies become more complex, the expectations around analytical characterization have shifted.
It’s no longer enough to demonstrate that something works under controlled conditions. Regulators (and sponsors themselves) are asking deeper questions. How consistent is the formulation? How does it behave over time? What happens under stress conditions? Are there subtle variations that could impact the safety or efficacy of a drug product?
For modalities like RNA-based therapies or nanoparticle systems, those questions aren’t hypothetical. Small differences in structure or composition can lead to meaningful changes in performance.
That puts analytical development in a very different position than it held even a few years ago. It’s no longer a downstream activity, it’s part of the core development strategy.
Stability studies tend to be viewed as a requirement to satisfy later-stage milestones. But in practice, they often reveal issues much earlier than expected.
A formulation that looks promising initially may behave very differently over time. Degradation pathways emerge, and physical characteristics could shift. In some cases, the product simply doesn’t hold up under the conditions it will ultimately face.
Catching those issues early can save significant time and expedite the development process. Missing them can create major delays—especially if they surface after a process has already been scaled.
Ascendia Pharmaceutical Solutions’ approach to stability tends to be more integrated into development, rather than treated as a separate phase. That allows our scientists to adjust formulations in response to real data, instead of reacting to problems after they’ve already taken shape.
While a lot of attention is focused on advanced modalities, there’s still a significant portion of the industry working with oral and modified release dosage forms, and those come with their own set of challenges.
Poorly soluble compounds, variable absorption, and the need for controlled release profiles all require careful formulation design. - Unlike some newer modalities, these challenges are often compounded by expectations around scalability and cost.
Ascendia Pharmaceutical Solutions’ work in this area doesn’t get as much attention as its nanotechnology platforms, but it addresses a very real need. Many programs still depend on getting oral delivery right, and doing so in a way that remains consistent across batches and over time.
There’s a category of work in drug development that’s often labeled as routine: method development, validation, and scale-up support. But that label can be misleading.
These steps may be common, but they’re not simple. And, when they’re not handled carefully, they can slow a program down just as much as more complex technical challenges.
Analytical methods that don’t fully capture variability can lead to rework later. Processes that aren’t designed with scale in mind can create complications during manufacturing. Even small variations in development workflows can add up over time.
What looks routine on paper often becomes a bottleneck in practice.
One of the risks with these less visible aspects of development is that they’re often treated in isolation. Analytical work is handed off to one group, formulation to another, stability to a third.
But the reality is that these pieces are closely connected.
Analytical insights should inform formulation decisions. Stability data should influence how a product is manufactured and stored. Development strategies should reflect what will ultimately be required during scale-up and manufacturing.
When those connections are maintained, adjustments can happen earlier and more efficiently. When they’re not, teams end up revisiting decisions that seemed settled.
The current environment in drug development leaves less room for inefficiency.
Timelines are tighter. Programs are more complex. Expectations, from both regulators and investors, are higher. That combination puts pressure not just on innovation, but also on execution and meeting the timeline.
The work that happens behind the scenes (analytical development, stability testing, formulation refinement) plays a larger role in that execution than it often gets credit for.
At a glance, many development programs look similar. There’s a progression from early work into clinical stages, with defined milestones along the way.
What’s harder to see is how much of that progress is linear, and how much involves revisiting earlier steps.
The more that foundational work is done thoughtfully, especially in areas that don’t always get the spotlight, the more likely a program is to move forward without an impediment.
That’s not about perfection. It’s about a streamlined process achieved by reducing the number of repetitive steps, reassessing, and rebuilding the entire process.
And in the current landscape, that can make a meaningful difference in how quickly (and how smoothly) a therapy reaches the clinic.